Fetuin-A-treated human islets display increased basal secretion, allowing the assumption that fetuin-A enforces a dematuration process, as increased basal secretion is characteristic of immature islets as well as of islets of humans with type 2 diabetes [1, 39]. The gene discussed is AHSG; the disease is type 2 diabetes mellitus.